Lucida Medical

Name: Lucida Medical
Brand: lucida

Lucida Medical Pi™ is an AI software medical device that analyzes prostate MRI to generate lesion segmentations and a risk score to support detection of clinically significant prostate cancer, biopsy decision-making, and prioritization of higher-risk cases.

Est 2019|Valuation $44.7M|Raised $23.1M|15 Ref Customers

Website|FTEs 30|HQ Cambridge, United Kingdom

Published Oct 13, 2026

01Common complaints

- US-only regulatory requirement - If procurement requires FDA 510(k) clearance today, Pi™ may not qualify (as of 2026 literature, Pi™ held CE Class IIb marking but not FDA clearance). - Non-standard imaging protocols / contraindicated populations - If workflows regularly use endorectal coils, non-PI-RADS protocols, or produce a high proportion of non-diagnostic scans, the product may be inapplicable or require additional governance. - Low-volume prostate MRI centers - Low prostate MRI volumes may weaken ROI given integration and validation overheads. - Buyers needing transparent list pricing - If published pricing is required for rapid vendor shortlisting, the vendor’s demonstration-led engagement model may be a procurement obstacle. - Organizations lacking capacity for clinical audit and model monitoring - Product instructions recommend auditing AI performance after scanner or protocol changes; lack of governance capacity increases deployment risk. - Current limitations acknowledged by the vendor / formal documentation constraints - Product instructions contain explicit warnings and contraindications and note that scanner/protocol variability can affect results. - Examples from documentation: - The software must not be used for certain patients (recent biopsy, prior treatment/surgery) and for poor-quality scans. - Documentation cautions about potential bias and recommends governance steps to ensure performance across populations. - The vendor recommends auditing and re-checking performance after MRI scanner, software, or protocol changes. - Features on the roadmap (not yet available) - The vendor has announced ongoing platform updates and potential expansion to additional cancer types; detailed roadmaps and timelines were not published in the materials reviewed. - Scale limitations - No public throughput or latency benchmarks for high-volume use cases (cloud vs on-prem performance not publicly benchmarked). - Security or compliance gaps - Public-facing security certifications and detailed enterprise security feature documentation are not clearly documented; procurement should request evidence. - API limitations or integration constraints - No public developer API documentation was found; integration appears to focus on PACS/RIS imaging workflows rather than open developer APIs.

Deal disqualifiers: what makes a POOR fit

Centers that routinely use endorectal coil imaging or non-standard protocols (contraindications in product documentation).
Environments that require FDA 510(k) clearance for procurement.

02Why they buy

- Competitive advantages validated by customer feedback (not just vendor claims) - Public third-party customer review content is limited; documented strengths are primarily study- and publication-driven rather than review-driven. - Unique features and capabilities competitors lack - No single feature was found that is demonstrably unique compared with competitor offerings. Several vendors offer lesion detection, segmentation, and risk outputs. Pi™’s emphasis on pathway-level decision support and UK multi-center validation evidence are notable aspects of its positioning. - Differentiation from competitors based on reviews - Not possible to derive from mainstream review platforms due to lack of independent review listings for Pi™. - Value propositions with evidence from case studies - Vendor and study materials link the AI score combined with clinical variables to potential reductions in unnecessary biopsies in validation cohorts; prospective operational evidence remains limited. - Areas where competitors clearly have advantages (be balanced) - US regulatory readiness: some competitors have FDA listings or clearances that matter for US procurements. - Vendor portfolio breadth: some competitors offer multi-organ imaging products, which can simplify enterprise vendor management.

03Field reports

- Availability reality check (important) - Radiology AI medical devices commonly have limited coverage on mainstream B2B review platforms. No verified product pages with user reviews for Pi™ were found on major industry review sites in the accessible searches for this research. - Direct quotes (where available) - Vendor-provided testimonial (vendor-provided; not independently verified): "Pi can identify the most clinically significant cancers and essentially allow me to offer a same day pathway…" — attributed by the vendor to a consultant interventional radiologist. This should be treated as a vendor-provided endorsement rather than independent evidence. - No independent external consumer review platform quotes were identified. - Community/social discussions (authentic feedback) — name-collision problem - Searches for "Lucida" on public forums returned unrelated content referring to other entities with similar names. Such results were excluded from product sentiment analysis. - General community discussion addresses prostate MRI quality and AI in imaging but did not provide site-level operational reviews of Pi™. - Why customers chose this product over alternatives (evidence level: moderate) - Factors referenced in public materials and innovation network write-ups include addressing radiologist capacity constraints, reducing waiting times, and supporting pathway speed; multi-center validation evidence (PAIR-1) and pilot/adoption support by innovation bodies are cited as adoption drivers. - Why some customers left for competitors (churn reasons) - No credible public sources documenting customer churn away from Pi™ were identified. - Specific outcomes customers achieved (with metrics when available) - Vendor-cited study results include PAIR-1 performance described as very high sensitivity with moderate specificity for clinically significant prostate cancer detection. Vendor announcements also reference a reported modest reduction in unnecessary biopsies when combining PI-RADS, PSA density, and the AI risk score in a validation cohort. These metrics originate from vendor-cited studies and should be validated against peer-reviewed publications and independent operational data where possible. - Deal-breakers and reasons customers didn’t purchase - Not available in public materials reviewed.

Case Studies

- Vendor-published customer story: Gemelli Hospital (Rome) - The vendor describes adoption within Gemelli Hospital’s radiology department and provides example cases where lesions were detected and later confirmed by biopsy. - Critical evaluation - This is vendor-published material and may be selective. It does not provide independent measurement of operational outcomes (e.g., reduced reporting time, reduced missed cancers, reduced biopsy volumes) at a service-line level. - NHS/innovation network writeups - Regional innovation networks describe supported trials and adoption and link the work to public funding and pathway improvement goals. - Critical evaluation - These bodies support adoption and may emphasize benefits; materials should be interpreted with understanding of their innovation-promotion remit. - Research evidence base (peer-reviewed) - A PAIR-1–related paper describing multi-centre validation for Pi™ v2.4 as a CE‑certified deep learning CAD medical device is publicly accessible. - Critical evaluation - Retrospective, multi-centre validation supports performance claims under study conditions, but retrospective validation does not alone demonstrate operational impact (workflow change, throughput, staffing effects). Conflict-of-interest disclosures in academic publications (e.g., relationships with the vendor) should be considered when assessing independence.

04Best fit

Company sizes (healthcare org sizing proxy)

Best fit appears to be mid-to-large hospital trusts and health systems with significant prostate MRI volumes and coordinated biopsy pathways.
In the UK: NHS Trusts and regional cancer alliances; in the EU: hospitals with established prostate MRI diagnostic pathways.

Industries and verticals where adoption is strongest

Public healthcare systems (notably the UK NHS) and European hospital radiology departments.

Roles and personas

Decision makers
- Clinical radiology leadership (uroradiology)
- Urology leadership (biopsy pathways)
- Imaging informatics and digital transformation leads
- Procurement and clinical safety officers
End users
- Radiologists reading prostate MRI
- Multidisciplinary teams coordinating prostate diagnostics

Pain points and challenges the product addresses

Radiologist capacity constraints and reporting variability
Biopsy pathway efficiency (reducing unnecessary biopsies while identifying clinically significant cancers)
Consistent triage and prioritization of cases

Qualification criteria: what makes a GREAT fit

Standardized PI‑RADS v2.1–compliant MRI protocols and sufficient image quality (aligns with product instructions).
Sites able to support PACS/RIS integration and clinical audit processes.

Real customer examples (where available)

Registries list research deployments at NHS trusts (e.g., Nottingham University Hospitals; University Hospitals of Derby and Burton). Vendor materials reference NHS Trust rollouts in several regions, though public details on production-scale deployment vary.

05The pitch

What the product does (core value proposition in objective terms)

- Lucida Medical’s Prostate Intelligence (Pi™) is an AI software medical device designed to assist clinicians in the interpretation of prostate MRI for suspected prostate cancer. - The vendor describes Pi™ as software intended to support the prostate cancer diagnostic pathway by helping clinicians detect clinically significant prostate cancer, supporting biopsy decisions, and prioritizing higher-risk patients while identifying lower-risk cases (decision support / "secondary read"). - Vendor-published performance highlights report very high sensitivity and moderate specificity for detecting clinically significant prostate cancer in the PAIR-1 study. The vendor also claims Pi™ performs at a level comparable to expert radiologists.

Target market and market positioning

Target users are healthcare professionals (radiologists/uroradiologists and other prostate diagnostic pathway stakeholders). The vendor states Pi™ is not intended for members of the public or patients.
Market positioning: clinical decision support / radiology AI focused specifically on prostate MRI within the diagnostic pathway (triage, biopsy prioritization, workflow support), with primary focus on UK NHS and EU contexts and stated intent to expand.

Get a comprehensive analysis of Lucida Medical including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →